Current trends in the structure-activity relationship studies of the endogenous agouti-related protein (AGRP) melanocortin receptor antagonist

Agouti‐related protein (AGRP) is an endogenous antagonist of the melanocortin‐3 and ‐4 (MC3R and MC4) G‐protein coupled receptors. The 87–132 amino acid C‐terminal domain of hAGRP possesses five disulfide bridges and a well‐defined three‐dimensional structure that displays full biological activity a...

Full description

Saved in:
Bibliographic Details
Published in:Medicinal research reviews 2005-09, Vol.25 (5), p.545-556
Main Authors: Wilczynski, Andrzej M., Joseph, Christine G., Haskell-Luevano, Carrie
Format: Article
Language:English
Subjects:
Agouti Signaling Protein
Agouti-Related Protein
AGRP
Animals
G-protein coupled receptors
Humans
ICK domain
Intercellular Signaling Peptides and Proteins - metabolism
melanocortin receptors
Models, Chemical
Proteins - chemistry
Proteins - metabolism
Proteins - pharmacology
Receptors, Melanocortin - antagonists & inhibitors
Receptors, Melanocortin - metabolism
Structure-Activity Relationship
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Agouti‐related protein (AGRP) is an endogenous antagonist of the melanocortin‐3 and ‐4 (MC3R and MC4) G‐protein coupled receptors. The 87–132 amino acid C‐terminal domain of hAGRP possesses five disulfide bridges and a well‐defined three‐dimensional structure that displays full biological activity as compared to the full‐length protein. Based on the NMR structure of the C‐terminal AGRP(87–132), a novel mini‐protein, referred to as “Mini‐AGRP” was designed that exhibited receptor binding affinity and antagonism similar to that of the parent hAGRP(87–132) protein. It was demonstrated that this new‐engineered protein autonomously folds to the inhibitor cystine knot (ICK) motif. As this AGRP is a novel mammalian protein involved in energy homeostasis and possibly other physiological functions remaining to be identified, structure‐function studies are starting to emerge toward the understanding of how this unique protein putatively interacts with the melanocortin receptors with the objective of designing potential therapeutic agents for in vivo physiological studies. This article summarizes the progress to date of AGRP‐based structure–activity relationships and putative ligand–receptor interactions. © 2005 Wiley Periodicals, Inc.
ISSN:0198-6325
1098-1128
DOI:10.1002/med.20037